Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats

Journal of Pharmacological Sciences

Volumn 107, Issue 3, 2008, Pages 340-348

  Matsumoto, Takafumi ^a   Ono, Yoshiyuki ^a   Kuromiya, Akemi ^a   Toyosawa, Kaoru ^a   Ueda, Yoshinaka ^a   Bril, Vera ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Aldose reductase inhibition; Cataract; Diabetic neuropathy; Ranirestat (AS 3201)

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; MYELIN; POLYOL; RANIRESTAT; SORBITOL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; CATARACT; CATARACTOGENESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET; DRUG POTENCY; HISTOPATHOLOGY; LENS; LONG TERM CARE; MALE; MORPHOLOGY; MORPHOMETRICS; MOTOR NERVE CONDUCTION; MYELINATION; NERVE FIBER; NONHUMAN; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; SURAL NERVE; TREATMENT RESPONSE;

EID: 47749146137     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08071FP     Document Type: Article

References (32)

1. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res. 2007;2007:61038.
2. Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem. 2003;10:1329-1352.
3. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14-36.
4. Perkins BA, Bril V. Emerging therapies for diabetic neuropathy: a clinical overview. Curr Diabetes Rev. 2005;1:271-280.
5. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10:99-108.
6. Kametaka S, Kasahara T, Ueo M, Takenaka M, Saito M, Sakamoto K, et al. A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats. J Pharmacol Sci. 2008;106:144-151.
7. Zatechka DS Jr, Kador PF, Garcia-Castiñeiras S, Lou MF. Diabetes can alter the signal transduction pathways in the lens of rats. Diabetes. 2003;52:1014-1022.
8. LinksRicheti F, Noronha RM, Waetge RT, de Vasconcellos JP, de Souza OF, Kneipp B, et al. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis. 2007;23:740-745.
9. Bloomgarden ZT. Screening for and managing diabetic retinopathy: current approaches. Am J Health Syst Pharm. 2007;64: S8-S14.
10. Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy. Acta Clin Belg. 2007;62:278-290.
11. Ii S, Ohta M, Kudo E, Yamaoka T, Tachikawa T, Moritani M, et al. Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency. Diabetologia. 2004;47:541-548.
12. Matsuoka K, Sakamoto N, Akanuma Y, Hotta N, Shichiri M, Toyota T, et al. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT). Diabetes Res Clin Pract. 2007;77: S263-S268.
13. Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, et al. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care. 2004;27:1153-1159.
14. Hotta N, Yasuda K, Sumita Y, Sano T, Kakuta H, Nagashima M, et al. Effects of a novel aldose reductase inhibitor, fidarestat (SNK-860), on vibration perception threshold and subjective symptoms in patients with diabetic polyneuropathy: an open-label pilot study. Clin Drug Investig. 2004;24:671-680.
15. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensori-motor polyneuropathy. Diabetes Care. 2006;29:68-72.
16. Clements RS Jr, Morrison AD, Winegrad AI. Polyol pathway in aorta: regulation by hormones. Science. 1969;166:1007-1008.
17. Sharma AK, Thomas PK. Peripheral nerve structure and function in experimental diabetes. J Neurol Sci. 1974;23:1-15.
18. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, et al. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism. 1991;40:77-87.
19. Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci. 2008; 107:231-237.
20. Sharma AK, Thomas PK. Animal models: pathologyand pathophysiology. In: Dyck PJ, Thomas PK, Ashbury AK, Winegrad AL, Porte D Jr, editors. Diabetic neuropathy. Philadelphia: Saunders; 1987. p. 237-252.
21. Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn J Pharmacol. 1997;73:133-144.
22. Cameron NE, Leonard MB, Ross IS, Whiting PH. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia. 1986;29:168-174.
23. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ. Effects of longterm aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes. 1990;39:690-696.
24. Sugimura K, Windebank AJ, Natarajan V, Lambert EH, Schmid HH, Dyck PJ. Interstitial hyperosmolarity may cause axis cylinder shrinkage in streptozotocin diabetic nerve. J Neuro-pathol Exp Neurol. 1980;39:710-721.
25. Qiang X, Satoh J, Sagara M, Fukuzawa M, Masuda T, Sakata Y. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia. 1998;41: 1321-1326.
26. Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract. 2000;50:77-85.
27. Kamijo M, Basso M, Cherian PV, Hohman TC, Sima AA. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. Diabetes Res Clin Pract. 1994;25:117-129.
28. Waxman SG. Determinants of conduction velocity in myelinated nerve fibers. Muscle Nerve. 1980;3:141-150.
29. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology. 1999;53:580-591.
30. Clark TA, Heyliger CE, Edel AL, Goel DP, Pierce GN. Codelivery of a tea extract prevents morbidity and mortality associated with oral vanadate therapy in streptozotocin-induced diabetic rats. Metabolism. 2004;53:1145-1151.
31. Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, et al. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007;23:116-123.
32. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002;19:278-285.